This website uses cookies to ensure you get the best experience on our website.
Privacy Statement


HCmed keeps you up-to-date with the most recent events and publications about the company and inhalation therapy




HCmed Innovations Prepares to Register in the Taiwan Emerging Stock Market

HCmed Innovations Co., Ltd. (6934) is pleased to announce that it has recently become a public company in Taiwan. The contract development and manufacturing organization (CDMO) that focuses on drug-nebulizer combination product development plans to register as an Emerging Stock company in 2023.

Founded in 2014, HCmed Innovations Co., Ltd. (HCmed) focuses on the development of drug-nebulizer combination products for inhalation therapy. As a full-service CDMO, HCmed provides a wide range of services with two customizable nebulizer platforms and aerosol characterization services to support the development process, mass production of nebulizers, and post-market surveillance (PMS).

As one of the few companies in the world that specializes in the development of drug-nebulizer combination products, HCmed supports global pharmaceutical partners with its high-quality nebulizer technology and customization capabilities. As HCmed continuously collaborates with various global partners, these projects are expected to contribute to HCmed’s operations and revenue.